JRS PHARMA has announced worldwide release of the Povidone Family product line, the latest addition to its excipients portfolio.

This product line consists of three products:

  • VIVAPHARM® PVP (Povidone), a wet binder with optimal balance between adhesive strength and ease-of-handling
  • VIVAPHARM® PVP/VA 64 (Copovidone), a tablet binder for processing technologies
  • VIVAPHARM® PVPP (Crospovidone), offering disintegration performance and versatility

JRS PHARMA’s global director of research and development (R&D) Dr. Gernot Warnke shared he is "excited about the addition of povidones to the portfolio, which strengthens our offering in the field of tablet binding and disintegration. The Povidone Family significantly contributes to building the most comprehensive range of solid dosage form excipients on the market."

Manufactured in a state-of-the-art good manufacturing practice (GMP) and ISO 9001 compliant/certified production facility, JRS PHARMA’s VIVAPHARM® Povidone range complies with the current Povidone, Copovidone, and Crospovidone monographs in Ph. Eur. 9.0, USP39/NF34, and JP17/JPE, respectively.

The specifications for the VIVAPHARM® Povidone range are set tighter than compendial limits to better meet customer requirements. A significant emphasis has also been placed on stringent quality control.

In addition to on-site quality checks, VIVAPHARM® Povidone products will go through final quality control and release in the newly established Analytical Competence Center at the JRS PHARMA facilities in Germany.

The VIVAPHARM® Povidone range will be warehoused in the JRS PHARMA Central Logistics Center in Germany and the US, enabling ease and speed-of-delivery. Samples of three batches of each product type are now available in 400g aluminum bags.